Related Experiment Videos
Development of malignant hyperthermia during mitral valve replacement
R D Quinn1, W E Pae, S A McGary
1Division of Cardiothoracic Surgery, Pennsylvania State University College of Medicine, Hershey 17033.
The Annals of Thoracic Surgery
|June 11, 1992
Summary
Malignant hyperthermia, a severe reaction to anesthesia, was diagnosed in a patient with centronuclear myopathy during heart surgery. Early recognition and management are crucial for potentially fatal cases, especially during cardiopulmonary bypass.
Area of Science:
- Anesthesiology
- Genetics
- Cardiology
Background:
- Malignant hyperthermia (MH) is a pharmacogenetic disorder triggered by volatile anesthetics and succinylcholine.
- Early diagnosis of MH is critical but challenging due to non-specific symptoms, particularly during cardiopulmonary bypass.
- Centronuclear myopathy (CNM) is a rare genetic muscle disorder, with limited reported associations with MH.
Observation:
- A case of MH is presented in a patient undergoing mitral valve replacement.
- The patient had an underlying diagnosis of centronuclear myopathy.
- Diagnosis was confirmed by intraoperative findings of increased oxygen consumption despite hypothermic cardiopulmonary bypass.
Findings:
- Malignant hyperthermia was successfully diagnosed during cardiopulmonary bypass in a patient with centronuclear myopathy.
- Intraoperative monitoring revealed increased oxygen consumption, a key indicator of MH, even under hypothermic conditions.
- The co-occurrence of MH and centronuclear myopathy in this case is rare.
Implications:
- This case highlights the importance of vigilance for MH in patients with rare myopathies undergoing cardiac surgery.
- It underscores the diagnostic utility of metabolic monitoring during cardiopulmonary bypass for MH detection.
- Improved understanding of MH in specific myopathies can refine anesthetic management and patient safety protocols.